GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ME Therapeutics Holding Inc (XCNQ:METX) » Definitions » ROA %

ME Therapeutics Holding (XCNQ:METX) ROA % : -62.34% (As of Feb. 2024)


View and export this data going back to 2023. Start your Free Trial

What is ME Therapeutics Holding ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. ME Therapeutics Holding's annualized Net Income for the quarter that ended in Feb. 2024 was C$-0.57 Mil. ME Therapeutics Holding's average Total Assets over the quarter that ended in Feb. 2024 was C$0.92 Mil. Therefore, ME Therapeutics Holding's annualized ROA % for the quarter that ended in Feb. 2024 was -62.34%.

The historical rank and industry rank for ME Therapeutics Holding's ROA % or its related term are showing as below:

XCNQ:METX' s ROA % Range Over the Past 10 Years
Min: -1684.75   Med: -913.95   Max: -143.14
Current: -880.3

During the past 2 years, ME Therapeutics Holding's highest ROA % was -143.14%. The lowest was -1684.75%. And the median was -913.95%.

XCNQ:METX's ROA % is ranked worse than
98.78% of 1552 companies
in the Biotechnology industry
Industry Median: -34.765 vs XCNQ:METX: -880.30

ME Therapeutics Holding ROA % Historical Data

The historical data trend for ME Therapeutics Holding's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ME Therapeutics Holding ROA % Chart

ME Therapeutics Holding Annual Data
Trend Aug22 Aug23
ROA %
-143.14 -1,684.75

ME Therapeutics Holding Quarterly Data
Aug22 Dec22 May23 Aug23 Nov23 Feb24
ROA % Get a 7-Day Free Trial -52.53 -2,180.97 -1,795.58 -240.07 -62.34

Competitive Comparison of ME Therapeutics Holding's ROA %

For the Biotechnology subindustry, ME Therapeutics Holding's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ME Therapeutics Holding's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ME Therapeutics Holding's ROA % distribution charts can be found below:

* The bar in red indicates where ME Therapeutics Holding's ROA % falls into.



ME Therapeutics Holding ROA % Calculation

ME Therapeutics Holding's annualized ROA % for the fiscal year that ended in Aug. 2023 is calculated as:

ROA %=Net Income (A: Aug. 2023 )/( (Total Assets (A: Aug. 2022 )+Total Assets (A: Aug. 2023 ))/ count )
=-6.52/( (0.102+0.672)/ 2 )
=-6.52/0.387
=-1,684.75 %

ME Therapeutics Holding's annualized ROA % for the quarter that ended in Feb. 2024 is calculated as:

ROA %=Net Income (Q: Feb. 2024 )/( (Total Assets (Q: Nov. 2023 )+Total Assets (Q: Feb. 2024 ))/ count )
=-0.572/( (0.471+1.364)/ 2 )
=-0.572/0.9175
=-62.34 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Feb. 2024) net income data. ROA % is displayed in the 30-year financial page.


ME Therapeutics Holding  (XCNQ:METX) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Feb. 2024 )
=Net Income/Total Assets
=-0.572/0.9175
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-0.572 / 0)*(0 / 0.9175)
=Net Margin %*Asset Turnover
=N/A %*0
=-62.34 %

Note: The Net Income data used here is four times the quarterly (Feb. 2024) net income data. The Revenue data used here is four times the quarterly (Feb. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


ME Therapeutics Holding ROA % Related Terms

Thank you for viewing the detailed overview of ME Therapeutics Holding's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


ME Therapeutics Holding (XCNQ:METX) Business Description

Comparable Companies
Traded in Other Exchanges
Address
177 Robson Street, Vancouver, BC, CAN, V6B 0N3
ME Therapeutics Holding Inc operates its business through ME Therapeutics. It is a preclinical-stage biotechnology company working on novel cancer-fighting drugs in the field of Immuno-Oncology (IO). It is developing preclinical data for its myeloid-targeted candidate assets using validated cancer models.

ME Therapeutics Holding (XCNQ:METX) Headlines

No Headlines